AlphaRx's Vansolin(TM) On Track To Enter Human Trials in '08
In the recent clinical trial, mice treated with Vansolin(TM) in a MurineModel of Pneumonia showed better efficacy than Vancomycin, achieving 100%survival rate vs. 30% in the Vancomycin treatment group. With these results,Vansolin(TM) is now on track to enter into human trials in 2008.
These results support The Company's belief that encapsulating Vancomycininto AlphaRx's nano-particle formulation may increase its efficacy. Accordingto published research papers, in vitro uptake of Vancomycin nanoparticles bywhite blood cells is 20 times greater than free drug. The Company anticipatesthat in vivo, after IV infusion, white blood cells will readily absorbVansolin nanoparticles and transport them to the site of inflammation andinfection, thereby increasing the local concentration of Vancomycin andultimately increasing its bactericidal effect.
What's more, in the Murine Model of Pneumonia, Vancomycin encapsulated inthe company's Nano Drug Delivery platform administrated by injection of 1mg/kg, is more effective than injecting 10 mg/kg, in a conventionalformulation in terms of mortality. The 90% reduction in dosage is significant,in that it may reduce potential toxicity effects of Vancomycin and may reducetreatment days from 10 days to 3 days.
Currently, the Company has four nano products in the development pipelinewith an estimated annual market sales potential of over US$6.0 billiondollars.
About AlphaRx Inc.
AlphaRx is a specialty pharmaceutical company utilizing proprietarysite-specific nanoparticulate drug delivery systems to develop novelformulations of drugs that are insoluble or poorly soluble in water or haveyet to be administrable to the human body with an acceptable delivery method.The Company also discovers and develops novel, small-molecule drugs for thetreatment of inflammatory diseases and neurodegenerative diseases.
Forward Looking Statements:
This release contains forward-looking statements within the meaning andpursuant to the Safe Harbor provisions of the Securities Litigation Reform Actof 1995 and involve risks and uncertainties that may individually or mutuallyimpact the matters herein described, including but not limited to productdevelopment and acceptance, manufacturing, competition, regulatory and/orother factors, which are outside the control of the companies.
SOURCE AlphaRx Inc.
You May Also Like